Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1

Karidia Diallo; Maureen Oliveira; Daniela Moisi; Bluma Brenner; Mark A Wainberg; Matthias Götte

doi:10.1128/AAC.46.7.2254-2256.2002

Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1

Antimicrob Agents Chemother. 2002 Jul;46(7):2254-6. doi: 10.1128/AAC.46.7.2254-2256.2002.

Authors

Karidia Diallo¹, Maureen Oliveira, Daniela Moisi, Bluma Brenner, Mark A Wainberg, Matthias Götte

Affiliation

¹ McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada.

Abstract

We cultured lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) variants over an extended period of time in the presence of zidovudine and observed a premature reversion of the resistance-conferring M184V mutation. These data suggest that the presence of ZDV amplifies differences in replication capacity between wild-type HIV-1 and the mutant variant.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / pharmacology*
Drug Resistance, Viral
HIV Reverse Transcriptase / genetics*
HIV-1 / drug effects*
Humans
Lamivudine / pharmacology*
Mutation*
Virus Replication / drug effects
Zidovudine / pharmacology*

Substances

Anti-HIV Agents
Lamivudine
Zidovudine
HIV Reverse Transcriptase